Cargando…

Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts

Molecular groups of medulloblastoma (MB) are well established. Novel risk stratification parameters include Group 3/4 (non-WNT/non-SHH) methylation subgroups I–VIII or whole-chromosomal aberration (WCA) phenotypes. This study investigates the integration of clinical and molecular parameters to impro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mynarek, Martin, Obrecht, Denise, Sill, Martin, Sturm, Dominik, Kloth-Stachnau, Katja, Selt, Florian, Ecker, Jonas, von Hoff, Katja, Juhnke, Björn-Ole, Goschzik, Tobias, Pietsch, Torsten, Bockmayr, Michael, Kool, Marcel, von Deimling, Andreas, Witt, Olaf, Schüller, Ulrich, Benesch, Martin, Gerber, Nicolas U., Sahm, Felix, Jones, David T. W., Korshunov, Andrey, Pfister, Stefan M., Rutkowski, Stefan, Milde, Till
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807480/ https://www.ncbi.nlm.nih.gov/pubmed/36459208 http://dx.doi.org/10.1007/s00401-022-02522-4

Ejemplares similares

MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS
por: Mynarek, Martin, et al.
Publicado: (2020)

EPEN-09. IMPACT OF MOLECULAR SUBGROUP ON OUTCOME FOR INFANTS <12 MONTHS WITH INTRACRANIAL EPENDYMOMA - GERMAN EXPERIENCE FROM HIT2000, INTERIM-2000-REGISTRY AND I-HIT-MED REGISTRY
por: Obrecht, Denise, et al.
Publicado: (2020)

Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies
por: Obrecht, Denise, et al.
Publicado: (2022)

MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy – Results of the MET-HIT2000-BIS4 trial
por: Mynarek, Martin, et al.
Publicado: (2022)

Defining the Spectrum, Treatment and Outcome of Patients With Genetically Confirmed Gorlin Syndrome From the HIT-MED Cohort
por: Kloth, Katja, et al.
Publicado: (2021)

QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL
por: Mynarek, Martin, et al.
Publicado: (2020)

RARE-12. Pineoblastoma of children and young adults in a national population: An analysis of the HIT-MED study cohort
por: Yuan, Mathias, et al.
Publicado: (2022)

EPEN-39. CLINICAL STRATIFIED TREATMENT OF LOCALIZED PEDIATRIC INTRACRANIAL EPENDYMOMA WITH COMBINED LOCAL IRRADIATION AND CHEMOTHERAPY WITHIN THE PROSPECTIVE, MULTICENTER E-HIT TRIAL – THE MOLECULAR SUBGROUP MATTERS
por: von Hoff, Katja, et al.
Publicado: (2020)

MBCL-07. NON-METASTATIC MEDULLOBLASTOMA OF EARLY CHILDHOOD: RESULTS FROM THE PROSPECTIVE CLINICAL TRIAL HIT-2000 AND AN EXTENDED VALIDATION COHORT
por: Mynarek, Martin, et al.
Publicado: (2020)

Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort
por: Pietsch, Torsten, et al.
Publicado: (2014)

MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate
por: Tonn, Svenja, et al.
Publicado: (2022)

PATH-07. QUALITY ASSURANCE IN CEREBROSPINAL FLUID CYTOLOGY ASSESSMENT FOR MEDULLOBLASTOMA STAGING LEADS TO POTENTIAL IMPROVED RISK-GROUP ASSESSMENT IN THE PROSPECTIVE MULTICENTER HIT-2000 TRIAL
por: Hagel, Christian, et al.
Publicado: (2020)

MEDB-37. Chemotherapy response prediction by molecular risk factors in metastatic childhood medulloblastoma
por: Obrecht, Denise, et al.
Publicado: (2022)

ETMR-14. TREATMENT OF EMBRYONAL TUMOURS WITH MULTILAYERED ROSETTES (ETMR) WITH CARBOPLATIN-ETOPOSIDE INDUCTION AND TANDEM HIGH-DOSE CHEMOTHERAPY WITHIN THE PROSPECTIVE HIT-TRIALS AND REGISTRIES
por: Juhnke, Björn-Ole, et al.
Publicado: (2020)

Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial
por: Goschzik, Tobias, et al.
Publicado: (2018)

MEDB-51. Impact of residual tumor on outcomes in children and adolescents with medulloblastoma in the German HIT-cohort
por: Wolgast, Stella, et al.
Publicado: (2022)

MBCL-09. ISOLATED M1 METASTASES IN PEDIATRIC MEDULLOBLASTOMA: IS POSTOPERATIVE RADIOTHERAPY FOLLOWED BY MAINTENANCE CHEMOTHERAPY SUPERIOR TO POSTOPERATIVE SANDWICH-CHEMOTHERAPY AND RADIOTHERAPY?
por: Obrecht, Denise, et al.
Publicado: (2020)

Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype
por: Kresbach, Catena, et al.
Publicado: (2021)

Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study
por: Gaab, Christine, et al.
Publicado: (2022)

Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment
por: Ottensmeier, Holger, et al.
Publicado: (2020)

MEDB-38. Significance of CSF cytology and neurologic deterioration in relapsed medulloblastomas in the German HIT-REZ-97/-2005 Studies and the HIT-REZ-Register
por: Tschirner, Sebastian, et al.
Publicado: (2022)

P1674: CLINICAL IMPACT OF NON-ADHERENCE TO HIT GUIDELINES: A DOUBLE HIT IN HIT
por: Al Raizah, A., et al.
Publicado: (2022)

Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies
por: Adolph, Jonas E., et al.
Publicado: (2021)

MBCL-11. TIME TO RADIOTHERAPY IMPACTS SURVIVAL IN PEDIATRIC AND ADOLESCENT NON-METASTATIC MEDULLOBLASTOMA TREATED BY UPFRONT RADIOTHERAPY – A REPORT FROM THE HIT 2000 TRIAL
por: Dietzsch, Stefan, et al.
Publicado: (2020)

HGG-16. Final analysis of the HIT-HGG-2007 trial (ISRCTN19852453): Significant survival benefit for pontine and non-pontine pediatric high-grade gliomas in comparison to previous HIT-GBM-C/-D trials.
por: von Bueren, Andrè O, et al.
Publicado: (2022)

QOL-24. DIFFERENTIAL IMPACT OF TUMOR LOCATION, LOCAL AND CRANIOSPINAL IRRADIATION ON NEUROPSYCHOLOGICAL LONG-TERM OUTCOME IN CHILDREN WITH MEDULLOBLASTOMA, EPENDYMOMA AND SUPRATENTORIAL PNET: A LONGITUDINAL MULTICENTER OUTCOME ASSESSMENT OF CHILDREN FROM THE HIT-2000 AND HIT-REZ TRIALS
por: Ottensmeier, Holger, et al.
Publicado: (2020)

Commentary: Getting HIT with HIT minus T (thrombosis without thrombocytopenia)
por: Edwin, Frank, et al.
Publicado: (2020)

EPEN-27. CDKN2A DELETION IN SUPRATENTORIAL EPENDYMOMA WITH RELA ALTERATION INDICATES A DISMAL PROGNOSIS – A RETROSPECTIVE ANALYSIS OF THE HIT EPENDYMOMA TRIAL COHORT
por: Jünger, Stephanie T, et al.
Publicado: (2020)

Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression
por: Korshunov, Andrey, et al.
Publicado: (2022)

Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features – a retrospective analysis of the HIT ependymoma trial cohort
por: Jünger, Stephanie T., et al.
Publicado: (2019)

CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort
por: Jünger, Stephanie T., et al.
Publicado: (2020)

The two-hit theory hits 50
por: Chernoff, Jonathan
Publicado: (2021)

EPEN-36. THE TREATMENT OUTCOME OF PAEDIATRIC SUPRATENTORIAL C11ORF95-RELA FUSED EPENDYMOMA: A COMBINED REPORT FROM E-HIT SERIES AND AUSTRALIAN NEW ZEALAND CHILDREN’S HAEMATOLOGY/ONCOLOGY GROUP
por: Ng, Chia Huan, et al.
Publicado: (2020)

The two "hit" and multiple "hit" theories of carcinogenesis.
por: Ashley, D. J.
Publicado: (1969)

MEDB-16. Persistent radiological lesions at the end of primary therapy in childhood medulloblastoma: residual lesion or active residual tumor?
por: Schömig, Lena, et al.
Publicado: (2022)

EPCT-06. PRECISION ONCOLOGY IN THE PEDIATRIC TARGETED THERAPY 2.0 PROGRAM
por: Ecker, Jonas, et al.
Publicado: (2021)

A Hit, a Hit—A Very Palpable Hit: Mild TBI and the Development of Epilepsy
por: Danzer, Steve C.
Publicado: (2019)

Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial
por: Clifford, Steven C., et al.
Publicado: (2015)

The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma
por: Ghasemi, David R., et al.
Publicado: (2022)

Greatest hits
Publicado: (1991)

Cannot write session to /tmp/vufind_sessions/sess_i7kgcdulhm173srl96cp92tlut